|
Market Closed -
NYSE
04:00:03 31/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 18.19 USD | -2.26% |
|
-1.89% | -23.67% |
| 10-22 | Arcus Biosciences Prices $250 Million Common Stock Offering; Shares Down Pre-Bell | MT |
| 10-21 | Wedbush Adjusts Price Target on Arcus Biosciences to $49 From $43, Keeps Outperform Rating | MT |
Company Valuation: Arcus Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,843 | 1,497 | 1,430 | 1,363 | 2,948 | 2,615 | - | - |
| Change | - | -47.33% | -4.52% | -4.7% | 116.38% | -11.31% | - | - |
| Enterprise Value (EV) 1 | 2,344 | 488.4 | 670.7 | 384.6 | 2,066 | 2,174 | 2,513 | 2,310 |
| Change | - | -79.16% | 37.34% | -42.66% | 437.29% | 5.22% | 15.57% | -8.09% |
| P/E | 57x | -5.57x | -4.6x | -4.74x | -7.24x | -5.13x | -5.47x | -5.94x |
| PBR | - | 2.29x | 3.12x | 2.83x | 4.73x | 8.42x | -25.3x | 6.34x |
| PEG | - | 0x | -0.4x | 0.2x | -1.52x | -0.66x | 0.89x | 0.75x |
| Capitalization / Revenue | 7.43x | 13.4x | 12.2x | 5.28x | 11.9x | 35.8x | 46.3x | 17.3x |
| EV / Revenue | 6.12x | 4.36x | 5.73x | 1.49x | 8.37x | 29.7x | 44.5x | 15.3x |
| EV / EBITDA | 40.3x | -1.78x | -2.02x | -1.28x | -5.5x | -4.84x | -5.44x | -6.92x |
| EV / EBIT | 43.2x | -1.74x | -1.97x | -1.17x | -5.35x | -4.6x | -5.62x | -5.12x |
| EV / FCF | -8.3x | 1.13x | - | -2.19x | -4.27x | -5.74x | -6.83x | -6.41x |
| FCF Yield | -12% | 88.5% | - | -45.8% | -23.4% | -17.4% | -14.6% | -15.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.71 | -3.71 | -4.15 | -3.14 | -3.29 | -3.545 | -3.328 | -3.064 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 382.9 | 112 | 117 | 258 | 247 | 73.15 | 56.52 | 150.9 |
| EBITDA 1 | 58.09 | -274 | -332 | -300 | -376 | -449.4 | -462 | -333.7 |
| EBIT 1 | 54.25 | -280 | -340 | -330 | -386 | -472.3 | -446.9 | -451.1 |
| Net income 1 | 52.83 | -267 | -307 | -283 | -353 | -448.9 | -413.2 | -401.4 |
| Net Debt 1 | -499.3 | -1,009 | -759 | -978 | -882 | -440.6 | -102.2 | -305.4 |
| Reference price 2 | 40.47 | 20.68 | 19.10 | 14.89 | 23.83 | 18.19 | 18.19 | 18.19 |
| Nbr of stocks (in thousands) | 70,249 | 72,408 | 74,856 | 91,512 | 123,729 | 143,762 | - | - |
| Announcement Date | 23/2/22 | 28/2/23 | 21/2/24 | 25/2/25 | 25/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.13x | 29.73x | -4.84x | -.--% | 2.62B | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.85x | 0.86% | 54.62B | |
| 34.93x | 3.32x | 14.34x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -64.56x | 13.05x | -73.23x | -.--% | 24.7B | |
| Average | 15.80x | 28.19x | 5.43x | 0.31% | 39.7B | |
| Weighted average by Cap. | 21.91x | 26.36x | 10.83x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RCUS Stock
- Valuation Arcus Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
